Management Change/Compensation Form 8 K

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 2, 2025, Todd P. Branning, the Interim Chief Executive Officer and Chief Financial Officer of NeuBase Therapeutics, Inc. (the "Company"), notified the Company of his resignation as interim Chief Executive Officer and Chief Financial Officer, effective as of close of business on January 3, 2025. Such resignation did not result from any disagreement with the Company on any matter relating to the Company's operations, policies or practices.

On January 4, 2025, Mr. Branning was appointed to the Board of Directors of the Company (the "Board"). There are no family relationships between Mr. Branning and any director or executive officer of the Company, and he was not selected by the Board to serve as a director pursuant to any arrangement or understanding with any person. Mr. Branning has not engaged in any transaction that would be reportable as a related party transaction under Item 404(a) of Regulation S-K.

On January 4, 2025, Dov A. Goldstein, M.D. notified the Company of his resignation as a member of the Board, effective immediately. Such resignation did not result from any disagreement with the Company on any matter relating to the Company's operations, policies or practices.